Propanc Biopharma (PPCB) 10-K 30 Sep 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Document Information [Line Items]
Entity Registrant Name	Propanc Health Group Corp
Entity Central Index Key	1,517,681
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PPCH
Entity Common Stock, Shares Outstanding		356,624,597
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 165,391

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Jun. 30, 2014
CURRENT ASSETS:
Cash	$ 107,627	$ 87,799
GST tax receivable	11,647	946
Prepaid expenses and other current assets	502,616	25,000
TOTAL CURRENT ASSETS	621,890	113,745
Security deposit	1,684	0
Property and equipment, net	3,494	0
TOTAL ASSETS	627,068	113,745
CURRENT LIABILITIES:
Accounts payable	236,466	350,004
Accrued expenses and other payables	386,311	422,326
Convertible notes and related accrued interest, net	1,794,375	272,424
Loans and notes payable	27,558	33,909
Embedded conversion option liabilities	780,281	0
Warrant derivative liability	269,648	158,244
Due to directors - related parties	35,108	60,350
Loans from directors and officer - related parties	79,416	161,975
Employee benefit liability	71,421	62,827
TOTAL CURRENT LIABILITIES	$ 3,680,584	$ 1,522,059
Commitments and Contingencies (See Note 9)
STOCKHOLDERS' DEFICIT:
Common stock, $0.001 par value; 2,000,000,000 shares authorized; 347,442,013 and 72,684,767 shares issued and outstanding as of June 30, 2015 and June 30, 2014, respectively	$ 347,442	$ 72,685
Additional paid-in capital	17,458,745	16,374,781
Accumulated other comprehensive income (loss)	100,968	(302,863)
Accumulated deficit	(20,965,671)	(17,552,917)
TOTAL STOCKHOLDERS' DEFICIT	(3,053,516)	(1,408,314)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	627,068	113,745
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value	5,000	0
TOTAL STOCKHOLDERS' DEFICIT	5,000	0
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value	0	0
TOTAL STOCKHOLDERS' DEFICIT	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	2,000,000,000	2,000,000,000
Common stock, issued shares	347,442,013	72,684,767
Common stock, outstanding shares	347,442,013	72,684,767
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	10,000,000	10,000,000
Preferred stock, issued shares	500,000	0
Preferred stock, outstanding shares	500,000	0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	5	5
Preferred stock, issued shares	1	0
Preferred stock, outstanding shares	1	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
REVENUE
Revenue	$ 0	$ 0
OPERATING EXPENSES
Administration expenses	1,567,549	742,037
Occupancy expenses	3,719	11,016
Research and development	134,319	8,168
TOTAL OPERATING EXPENSES	1,705,587	761,221
LOSS FROM OPERATIONS	(1,705,587)	(761,221)
OTHER INCOME (EXPENSE)
Interest expense	(1,323,902)	(93,147)
Interest income	33	18
Other expense	(50,002)	0
Change in fair value of derivative liabilities	(541,981)	(16,522)
Gain on debt settlements, net	375,547	0
Foreign currency transaction loss	(244,332)	(6,959)
TOTAL OTHER INCOME (EXPENSE)	(1,784,637)	(116,610)
LOSS BEFORE INCOME TAXES	(3,490,224)	(877,831)
INCOME TAX BENEFIT	77,470	48,267
NET LOSS	(3,412,754)	(829,564)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation gain (loss)	403,831	(58,274)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	$ (3,008,923)	$ (887,838)
BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)	$ (0.02)	$ (0.01)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING (in shares)	177,633,496	72,350,555

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Total	Common stock issuable [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Balance at Jun. 30, 2013	$ (792,476)	$ 25	$ 70,632	$ 16,104,809	$ (16,723,353)	$ (244,589)	$ 0	$ 0
Balance (in shares) at Jun. 30, 2013		25,000	70,632,267				0	0
Issuance of stock for services	244,500	$ (25)	$ 1,915	242,610	0	0	$ 0	$ 0
Issuance of stock for services (in shares)		(25,000)	1,915,000				0	0
Issuance of common stock for conversion of accrued expenses	27,500	$ 0	$ 138	27,362	0	0	$ 0	$ 0
Issuance of common stock for conversion of accrued expenses (in shares)		0	137,500				0	0
Foreign currency translation gain/loss	(58,274)	$ 0	$ 0	0	0	(58,274)	$ 0	$ 0
Net loss	(829,564)	0	0	0	(829,564)	0	0	0
Balance at Jun. 30, 2014	(1,408,314)	$ 0	$ 72,685	16,374,781	(17,552,917)	(302,863)	$ 0	$ 0
Balance (in shares) at Jun. 30, 2014		0	72,684,767				0	0
Issuance of common stock for cash	29,000	$ 0	$ 13,400	15,600	0	0	$ 0	$ 0
Issuance of common stock for cash (in shares)		0	13,400,000				0	0
Issuance of common stock for conversion of convertible debt	441,160	$ 0	$ 181,185	259,975	0	0	$ 0	$ 0
Issuance of common stock for conversion of convertible debt (in shares)		0	181,185,110				0	0
Issuance of stock for services	741,276	$ 0	$ 19,258	717,018	0	0	$ 5,000	$ 0
Issuance of stock for services (in shares)		0	19,258,316				500,000	1
Issuance of common stock as part of settlement agreement	152,285	$ 0	$ 60,914	91,371	0	0	$ 0	$ 0
Issuance of common stock as part of settlement agreement (in shares)		0	60,913,820				0	0
Foreign currency translation gain/loss	403,831	$ 0	$ 0	0	0	403,831	$ 0	$ 0
Net loss	(3,412,754)	0	0	0	(3,412,754)	0	0	0
Balance at Jun. 30, 2015	$ (3,053,516)	$ 0	$ 347,442	$ 17,458,745	$ (20,965,671)	$ 100,968	$ 5,000	$ 0
Balance (in shares) at Jun. 30, 2015		0	347,442,013				500,000	1

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,412,754)	$ (829,564)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance of common stock for services and voluntary ratchet	276,792	237,833
Issuance of preferred stock for services	1,067	0
Fair value of warrants issued for services	51,488	0
Gain on debt settlements, net	(375,547)	0
Settlement fees paid in the form of debt	150,000	0
Amortization of prepaid shares issued for services	0	6,667
Foreign currency transaction loss	31,548	0
Depreciation expense	81	538
Amortization of debt discount	295,795	49,029
Change in fair value of derivative liabilities	541,981	16,522
Accretion of put premium	1,044,196	27,187
Changes in Assets and Liabilities:
GST receivable	(10,879)	0
Prepaid expenses and other assets	(74,303)	294
Accounts payable	(47,977)	94,607
Employee benefit liability	20,362	11,598
Accrued expenses	115,941	158,847
Accrued interest	(34,270)	0
NET CASH USED IN OPERATING ACTIVITIES	(1,426,479)	(226,442)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for security deposit	(1,684)	0
Purchase of equipment	(3,901)	0
NET CASH USED IN INVESTING ACTIVITIES	(5,585)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft	0	(6)
Loan repayments to principal stockholder	(28,455)	(45,512)
Proceeds from convertible promissory notes	1,438,500	273,959
Repayments of convertible promissory notes	(157,000)	0
Proceeds from issuance of common stock for cash	29,000	0
Loan proceeds	0	10,542
Loan proceeds from principal stockholder	0	72,158
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,282,045	311,141
Effect of exchange rate changes on cash	169,847	3,100
NET INCREASE IN CASH	19,828	87,799
CASH AT BEGINNING OF YEAR	87,799	0
CASH AT END OF YEAR	107,627	87,799
Cash paid during the year:
Interest	0	0
Income Tax	0	0
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Common stock issued for settlement of debt	152,285	0
Prepaid common stock issued for services	269,682	6,667
Prepaid warrants issued for services	138,314	0
Reduction of put premium related to conversions of convertible note	71,370	0
Conversion of accrued expenses to common stock	0	27,500
Conversion of convertible notes and accrued interest to common stock	374,771	0
Discounts related to warrants issued with convertible debenture	0	133,095
Discounts related to lender costs	48,500	30,000
Discounts related to derivative liability	305,000	0
Conversion of loan payable to convertible debenture	0	27,963
Conversion of loan payable to common stock	66,389	0
Prepaid settlement fee paid through issuance of convertible note	$ 0	$ 25,000

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Propanc PTY LTD was incorporated in Melbourne, Victoria Australia on October 15, 2007, and is based in Richmond, Victoria Australia. Since inception, substantially all of the efforts of the Company have been the development of new cancer treatments targeting high risk patients who need a follow up, nontoxic, long term therapy which prevents the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. On November 23, 2010, Propanc Health Group Corporation ("the Company", "we", "us", "our") was incorporated in the state of Delaware. In January 2011, to reorganize the Company, Propanc Health Group Corporation acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary. The consolidated financial statements include the accounts of Propanc Health Group Corporation and its wholly-owned subsidiary, Propanc PTY LTD. All significant inter-company balances and transactions have been eliminated in consolidation. The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollars ($) and/or USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss as other income (expense). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Comprehensive income (loss) for all periods presented, includes only foreign currency translation gains (losses). Foreign Currency Items: Beginning balance, June 30, 2013 $ (244,589) Foreign currency translation loss (58,274) Balance, June 30, 2014 (302,863) Foreign currency translation gain 403,831 Ending balance, June 30, 2015 $ 100,968 The Company measures their financial assets and liabilities in accordance with US GAAP. For certain of the Company’s financial instruments, including cash and cash equivalents, accounts and other receivables, accounts payable and accrued expenses and other liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for loans payable, also approximate fair value because current interest rates available to us for debt with similar terms and maturities are substantially the same. The Company adopted accounting guidance for fair value measurements of financial assets and liabilities. The adoption did not have a material impact on the Company’s results of operations, financial position or liquidity. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of June 30, 2015 or 2014. As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of uncollectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis included the age of the receivable account, creditworthiness of the customer and general economic conditions. Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: Machinery and equipment 5 Patent costs are stated at cost and reclassified to intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency, however, the Company will expense any costs as long as the Company is in the startup stage. Accordingly, as the Company's product was and is not currently approved for market, thus any patent costs incurred from 2013 through 2015 were expensed immediately. Currently, the Company has one International patent pending which was jointly applied for by the Company and another entity. The Company received grant status , or been accepted in South Africa, Australia, and New Zealand. In addition, the United States Patent and Trademark Office or USPTO and European Patent Office or EPO have made preliminary indications that key features of the Company’s technology are patentable. The Company is presently working towards securing a patent in each region, covering as many aspects of its technology as possible, whilst also actively seeking protection throughout Eastern Europe, Asia and South America. Individual countries and regions where the Company is actively seeking patent protection include United States, Canada, Japan, Brazil, China, Mexico, Hong Kong, Singapore, Israel, Chile, Peru, Malaysia, Vietnam, Indonesia, Europe, Russia, India, and South Korea. The patent is now granted , or accepted in South Africa, Australia, and New Zealand. In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Liabilities arising in respect of wages and salaries, annual leave, accumulated sick leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months and therefore, recorded at nominal value. Revenues, expenses and balance sheet items are recognized net of the amount of GST except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2015 and June 30, 2014 the Company was owed $ 11,647 946 ASC Topic 815, Derivatives and Hedging The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480 and measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion, and records the put premium as accretion to interest expense to the date of first conversion. The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. The Company adopted provisions of ASC 740, Sections 25 through 60, “Accounting for Uncertainty in Income Taxes." These sections provide detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of ASC 740 and in subsequent periods. Upon the adoption of ASC 740, the Company had no unrecognized tax benefits. During the years ended June 30, 2015 and 2014 no adjustments were recognized for uncertain tax benefits. The years 2008 through 2015 are subject to examination by the Australian Taxation Office. The years ended June 30, 2012 through 2015 is subject to examination by the United States Internal Revenue Service. In accordance with ASC 730-10, research and development costs are expensed when incurred. Total research and development costs for the years ended June 30, 2015 and 2014 were $ 134,319 8,168 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income then the Company can receive the credit which reduces its income tax liability. If the Company has net losses then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During the years ended June 30, 2015 and 2014, the Company applied for and received from the Australian Taxation Office a research and development tax credit in the amount of $ 77,470 48,267 The Company records stock based compensation in accordance with ASC section 718, “Stock Compensation” and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “Equity-Based Payments to Non-Employees”. In accordance with SEC Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition, (codified in ASC 605) the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists or acceptance occurs, (ii) a retailer, distributor or wholesaler receives the goods, (iii) the price is fixed or determinable, and (iv) collectability of the sales revenues is reasonably assured. Subject to these criteria, the Company recognizes revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. In accordance with ASC 720-15-15, start-up costs are expensed as incurred. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. For the years ended June 30 2015 and 2014, there were 7,379,158 3,000,000 335,716,597 6,069,667 Financial Accounting Standards Board, Accounting Standard Updates which are not effective until after June 30, 2015 are not expected to have a significant effect on the Company’s consolidated financial position or results of operations. The Company implemented the following at June 30, 2015: In June 2014, the FASB issued ASU No. 2014-10, which amended Accounting Standards Codification (ASC) Topic 915 Development Stage Entities. The amendment eliminates certain financial reporting requirements surrounding development stage entities, including an amendment to the variable interest entities guidance in ASC Topic 810, Consolidation. The amendment removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other entities from U.S. GAAP. Consequently, the amendment eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This amendment is effective for fiscal years beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has made the election to early adopt this amendment effective June 30, 2014 and, as a result, the Company is no longer presenting or disclosing the information previously required under Topic 915. The early adoption was made to reduce data maintenance by removing all incremental financial reporting requirements for development stage entities. The adoption of this amendment alters the disclosure requirements of the Company, but it does not have any material impact on the Company's financial position or results of operations for the current or any prior reporting periods. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements – Going Concern (Topic 205-40)”, which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period. If substantial doubt exists, additional disclosure is required. This new standard will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to adopt this new standard as of December 31, 2015. The Company does not expect this ASU to have a material impact on its consolidated financial statements. On May 8, 2015, the FASB issued ASU 2015-08, “Business Combinations (Topic 805) Pushdown Accounting ” which conforms the FASB’s guidance on pushdown accounting with the SEC’s guidance. ASU 2015-08 is effective for annual periods beginning after December 15, 2015. The Company does not expect this ASU to have a material impact on its consolidated financial statements. In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs," which changes the presentation of debt issuance costs in financial statements. Under this guidance such costs would be presented as a direct deduction from the related debt liability rather than as an asset. This guidance is effective for interim and annual reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its Consolidated Balance Sheet, but expects that as of June 30, 2015 this guidance would not have a material effect on the consolidated balances current presentation.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Going Concern [Text Block]	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the year ended June 30, 2015, the Company had no revenues and had a net loss of $ 3,412,754 1,426,479 3,058,694 3,053,516 20,965,671 Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company's International patent application and achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investment or achieve an adequate sales level.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 3 – PROPERTY AND EQUIPMENT Property, plant, and equipment consist of the following as of June 30, 2015 2014 Office equipment at cost $ 15,732 $ 14,968 Less: Accumulated depreciation (12,238) (14,968) Total property, plant, and equipment $ 3,494 $ - Depreciation expense for the years ended June 30, 2015 and 2014 were $81 and $538 respectively.

DUE TO DIRECTORS - RELATED PART

DUE TO DIRECTORS - RELATED PARTIES	12 Months Ended
	Jun. 30, 2015
Due to Related Parties [Abstract]
Due To Directors Related Party [Text Block]	NOTE 4 – DUE TO DIRECTORS - RELATED PARTIES Due to directors - related parties represents unsecured advances made by the directors for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed these directors at June 30, 2015 and June 30, 2014 is $ 35,108 60,350 44,000 44,000 14,000

LOANS AND NOTES PAYABLE

LOANS AND NOTES PAYABLE	12 Months Ended
	Jun. 30, 2015
Notes and Loans Payable [Abstract]
Loans And Notes Payable Disclosure [Text Block]	NOTE 5 – LOANS AND NOTES PAYABLE Loans from Directors and Officer - Related Parties Loans from Directors and an Officer at June 30, 2015 and June 30, 2014 were $ 79,416 161,975 127,000 109,000 33,259,350 17,654,470 27,000 14,000 0.0025 127,284 86,455 28,500 Other Loans from Unrelated Parties Loans from two unrelated parties were received during 2013 totaling $ 33,614 10 27,963 A loan from an unrelated party was received during the year ended June 30, 2014 totaling $ 9,419 10 A loan from an unrelated party was received during the year ended June 30, 2014 totaling $ 18,839 Accordingly, other loans totaled $ 33,909 In July 2014, the loans and notes payable balance of $ 33,909 27,558 Debt Settlement to be Paid in Stock, Net of Premium In July 2014, the Company consolidated outstanding debt and other liabilities as part of a settlement agreement (See Note 9) and was indebted to one unrelated party for approximately $ 1,033,000 50,000 355,000 628,000 7,426,000 8,161,000 81,396 575,000 310,000 50,000 17,000 Notes Payable On July 18, 2014, the Company paid a $ 50,000 50,000 10,000,000 50,000 25,000 1,466 0.0025 25,000 51,466

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 6 – CONVERTIBLE NOTES June 30, 2015 June 30, 2014 Convertible notes and debenture $ 1,455,000 $ 366,296 Unamortized discounts (415,467) (121,059) Accrued interest 26,989 - Premium, net 727,853 27,187 Convertible notes, net $ 1,794,375 $ 272,424 On September 30, 2013 the Company’s subsidiary issued a Debenture for $ 139,680 150,000 3,000,000 12 27,963 63,196 46,446 0.075 0.0698 0.20 0.075 53 27 0.4 400,000 140,000 260,000 139,680 15,118 0.0709 0.075 2,183,333 On May 8, 2014, the Company issued a 10 25,000 25,000 25,000 1,466 On May 29, 2014, the Company issued a convertible note payable for $ 75,000 8 May 29, 2015 180 55 61,364 180 51,089 10,275 14,547 218 61,364 60,453 4,352 On May 29, 2014, the Company issued a second convertible note payable for $ 75,000 8 May 29, 2015 55 61,364 51,089 10,275 11,755 553 61,364 63,245 3,313 On May 30, 2014, the Company issued a third convertible note payable for $ 50,000 8 May 30, 2015 180 55 40,909 34,273 6,636 50,000 3,346 40,909 In addition to each of the above initial convertible promissory notes (“initial convertible notes”), the Company issued to each lender another convertible promissory note for the same amounts of $ 75,000 75,000 50,000 In the event the Company redeems the initial convertible notes in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by i) 130 140 150 In the event of two specific defaults, which include the maintenance of a minimum trading price and an aggregate dollar trading volume of the Company's common shares, the holders may cancel the Back-End Notes and the related Notes Receivable and otherwise in the event of other defaults as defined in the securities purchase agreement, the amount of principal and accrued interest will become immediately due and payable and may be offset by amounts due to the Company by the holders. Additionally, the Back-End Notes will bear default interest at a rate of 16 Since the Back-End Notes are not convertible until the Notes Receivable are paid and also not for 180 days from the note dates, and the Notes Receivable and Back-End Notes have a right of setoff, the Notes Receivable and Back-End Notes and related accrued interest receivable and payable have been netted for presentation purposes on the accompanying consolidated balance sheet. On August 6, 2014 (execution date), the Company executed a convertible promissory note in the principal sum of $ 250,000 25,000 10 0 12 0.09 60 12 2,134 250,000 On November 17, 2014, the Company issued a convertible promissory note for $ 43,000 8 August 20, 2015 180 58 31,138 27,851 61,632 43,000 1,527 17,105 3,287 On December 10, 2014, the Company issued a convertible promissory note for $ 28,000 8 September 12, 2015 180 58 20,276 15,657 38,654 28,000 853 9,801 4,619 On January 26, 2015, the Company issued a convertible promissory note for $ 28,000 8 October 28, 2015 180 58 20,276 15,432 37,137 28,000 835 8,302 4,844 On January 27, 2015, the Company received payment of the Note Receivable of $ 50,000 7,779 2,500 5,000 34,721 55 40,909 180 40,909 50,000 609 40,909 On February 10, 2015, the Company issued a convertible note payable for $ 45,000 7,500 8 February 10, 2016 180 55 36,818 27,409 1,391 On February 17, 2015, the Company issued a second convertible note payable for $ 45,000 7,500 8 February 17, 2016 180 55 36,818 27,409 1,322 On March 12, 2015, the Company issued a third convertible note payable for $ 170,500 13,000 8 March 12, 2016 55 139,500 4,148 On March 20, 2015, the Company issued a fourth convertible note payable for $ 150,000 8 March 20, 2016 55 122,727 3,386 In addition to each of the above initial convertible promissory notes (“initial convertible notes”), the Company issued to each lender another convertible promissory note for the same amounts of $ 45,000 45,000 170,500 150,000 In the event the Company redeems the initial convertible notes in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by i) 130 140 150 In the event of two specific defaults, which include the maintenance of a minimum trading price and an aggregate dollar trading volume of the Company's common shares, the holders may cancel the Back-End Notes and the related Notes Receivable and otherwise in the event of other defaults as defined in the securities purchase agreement, the amount of principal and accrued interest will become immediately due and payable and may be offset by amounts due to the Company by the holders. Additionally, the Back-End Notes will bear default interest at a rate of 24 Since the Back-End Notes are not convertible until the Notes Receivable are paid and also not for 180 days from the note dates, and the Notes Receivable and Back-End Notes have a right of setoff, the Notes Receivable and Back-End Notes and related accrued interest receivable and payable have been netted for presentation purposes on the accompanying consolidated balance sheet. On February 15, 2015, in connection with a six-month consulting agreement, the Company issued a convertible promissory note for $ 90,000 5 August 15, 2015 60 60,000 1,677 On February 20, 2015, the Company issued a convertible promissory note for $ 58,000 12 July 27, 2015 180 50 58,000 36,411 83,512 58,000 2,212 23,300 21,589 On March 12, 2015, the Company issued a convertible promissory note for $ 104,000 8 December 16, 2015 180 58 75,310 46,441 2,530 137,915 104,000 2,872 (See Note 13) On March 12, 2015, in connection with a two-year consulting agreement, the Company issued a convertible promissory note for $ 60,000 10 March 11, 2017 0.0175 75 1,825 On April 20, 2015, the Company issued a convertible note payable for $ 17,500 8 April 20, 2016 55 14,318 272 On April 24, 2015, the Company received payment of the Note Receivable of $ 45,000 7,500 2,250 35,250 55 36,818 180 13,909 671 On April 24, 2015, the Company received payment of the Note Receivable of $ 45,000 7,500 2,250 35,250 55 36,818 180 13,909 671 On April 27, 2015, the Company received payment of the Note Receivable of $ 170,500 13,000 7,500 150,000 55 139,500 2,429 On May 19, 2015, the Company entered into a Securities Purchase Agreement (“SPA”), to issue a series of nine back end convertible notes in the principal sum of $ 782,500 37,500 37,500 157,500 150,000 17,500 37,500 37,500 157,500 150,000 55 The Back-End Notes may not be prepaid, except that if the initial convertible notes are redeemed by the Company within six months of their issuance, all obligations of the Company and holders under the Back-End Notes and the Notes Receivable will be deemed satisfied and such notes shall automatically be deemed cancelled and of no further force or effect. In the event of two specific defaults, which include the maintenance of a minimum trading price and an aggregate dollar trading volume of the Company's common shares, the holders may cancel the Back-End Notes and the related Notes Receivable and otherwise in the event of other defaults as defined in the securities purchase agreement, the amount of principal and accrued interest will become immediately due and payable and may be offset by amounts due to the Company by the holders. Additionally, the Back-End Notes will bear default interest at a rate of 24% per annum, or the highest rate of interest permitted by law. Since the Back-End Notes are not convertible until the Notes Receivable are paid, and the Notes Receivable and Back-End Notes have a right of setoff, the Notes Receivable and Back-End Notes and related accrued interest receivable and payable have been netted for presentation purposes on the accompanying consolidated balance sheet. On June 2, 2015, the Company received payment of the Note Receivable of $ 150,000 7,500 142,500 55 122,727 2,137 On June 4, 2015 (execution date), the Company executed a convertible promissory note in the principal sum of $ 1,215,000 110,000 10 335,000 30,000 5,000 220,000 20,000 220,000 20,000 40 300,000 30,000 5,000 0.07 3,000,000 2,513 The Company recorded $ 529,500 30,000 114,033 3,133

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 7 – INCOME TAXES The Company follows ASC 740-10-10, under which an entity recognizes deferred tax assets and liabilities for future tax consequences or for events that were previously recognized in the Company’s financial statements or tax returns. The measurement of deferred tax assets and liabilities is based on enacted tax law provisions. The effects of future changes in tax laws or rates are not anticipated. As of June 30, 2015, the Company operated exclusively in Australia. The Company was wholly subject to Australia income tax laws and regulations, which are administered by the Australian Taxation Office for the years ended June 30, 2015 and 2014 and all prior years. On November 23, 2010, Propanc Health Group Corporation was incorporated in the state of Delaware. In January 2011, Propanc Health Group Corporation acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary. As a result of these transactions, the Company is subject to the income tax laws of both the United States and Australia for the years ended June 30, 2015 and 2014. For the years ended June 30, 2015 and 2014, all the Company’s loss before income taxes resulted entirely from its Australian activities and its taxable loss was only subject to Australian tax law. At June 30, 2015, the Company has a net operating loss (NOL) for Australian tax purposes only, that approximates $ 12,486,000 1,527,228 Year Ended June 30, June 30, 2015 2014 Current Taxes $ (77,470) $ (48,267) Deferred Taxes - - Income Taxes Expense (Benefit) $ (77,470) $ (48,267) Year Ended June 30, June 30, 2015 2014 Impact on Impact on Amount Rate Amount Rate Income Tax Expense (Benefit) at Australia Statutory Rate $ (672,087) (19.26) % $ (274,229) (31.24) % Expenses Paid by Parent on Behalf of Foreign Subsidiary 156,410 4.48 % 92,480 10.54 % R&D Refundable Tax Credit (77,470) (2.22) % (48,267) (5.50) % Reduction of NOL Carryforward Due to R&D Tax Credit 77,470 2.22 % 48,267 5.50 % Change in Deferred Tax Valuation Allowance (355,636) (10.19) % 260,533 29.68 % Foreign Exchange Rate Changes 793,843 22.74 % (127,051) (14.47) % Total Income Tax Expense (Benefit) $ (77,470) (2.22) % $ (48,267) (5.50) % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. June 30, June 30, 2015 2014 Current Deferred Tax Assets Warrant Derivative Liability $ 88,204 $ 28,209 Provision for Annual Leave 21,426 18,848 Superannuation - 3,815 Total Current Deferred Tax Assets $ 109,630 $ 50,872 Current Deferred Tax Liabilities Prepaid Investor Services $ - $ - Prepaid Expenses - - Prepaid Insurance - - Accounts Payable/Trade Creditors - - Patent Costs - - Total Current Deferred Tax Liabilities $ - $ - Non-Current Deferred Tax Assets Prepaid Investor Services $ 185,025 $ 751,917 Capital Raising Costs 23,261 28,622 Legal Costs 23,583 29,019 Intellectual Property 11,612 14,288 Patent Costs 59,995 59,473 Formation Expense 7,117 8,757 Net Operating Loss Carryover 3,426,149 3,259,060 Foreign Exchange Loss (OCI) (30,290) 90,859 Total Non-Current Deferred Tax Assets 3,706,452 4,241,995 Deferred Tax Valuation Allowance (3,816,082) (4,292,867) Total Non-Current Deferred Tax Assets (109,630) (50,872) Total Deferred Tax Assets (Net) $ - $ - Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company follows ASC 740-10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of June 30, 2015 the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended June 30, 2015 and 2014. The Company did not recognize any interest or penalties during fiscal 2015 or 2014 related to unrecognized tax benefits. The income tax returns filed for the tax years from inception will be subject to examination by the relevant taxing authorities.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – STOCKHOLDERS’ DEFICIT Preferred Stock: The total number of preferred shares authorized and that may be issued by the Company is 10,000,000 0.01 Of the total preferred shares authorized, pursuant to Certificate of Designation filed on December 9, 2014, 500,000 0.01 500,000 0.00213 1,067 8,161,000 Of the total preferred shares authorized, pursuant to Certificate of Designation filed on June 16, 2015, up to five (5) shares have been designated as Series B preferred stock, with a par value of $ 0.01 0.1165 0.12 This value represents the economic rights of the share as the value of voting rights, which represent control rights, are not objectively measureable. Common Stock: On November 12, 2014, the Company filed an amendment to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware, to increase the Company’s authorized common stock from one hundred million (100,000,000) shares of common stock, par value $ 0.001 0.001 0.001 0.001 In July 2013, the Company issued 300,000 0.20 12,000 48,000 In July 2013, the Company issued 250,000 0.20 50,000 In July 2013, the Company issued 137,500 27,500 0.20 In July 2013, the Company issued 10,000 0.20 2,000 In July 2013, the Company issued 150,000 0.20 30,000 In September 2013, the Company issued the balance of 300,000 0.20 60,000 On September 30, 2013, pursuant to a consulting agreement, the company issued 25,000 0.20 5,000 In October 2013, the Company issued 500,000 0.10 50,000 In October 2013, the Company issued 200,000 0.10 13,333 6,667 In October 2013, the Company issued 100,000 0.10 10,000 In November 2013, the Company issued 30,000 0.10 3,000 In November 2013, the Company issued 25,000 0.10 2,500 On May 9, 2014, the Company entered into an agreement with a consultant to provide services over a twelve month period in exchange for 1,000,000 0.10 100,000 500,000 500,000 100,000 On July 2, 2014, a $ 139,680 154,798 0.0709 2,183,333 On September 11, 2014, the Company issued 7,426,000 On October 17, 2014, the Company entered into an agreement with a consultant to provide services over a six month period. The Company agreed to issue the consultant 4,000,000 3,000,000 3,000,000 10,000,000 0.008 80,000 4,000,000 6,000,000 80,000 On November 4, 2014, the Company issued 8,161,000 On November 5, 2014, the Company entered into a private placement securities purchase agreement with an accredited investor pursuant to which the Company agreed to issue up to 3,000,000 0.001 3,000 3,000,000 On December 9, 2014, pursuant to a conversion notice, $ 5,357 0.0011 4,870,391 On December 10, 2014, pursuant to a conversion notice, $ 7,368 0.0011 6,698,331 On December 11, 2014, the Company entered into a private placement securities purchase agreement with an accredited investor pursuant to which the Company agreed to issue up to 1,000,000 0.0025 2,500 On December 16, 2014, the Company entered into a private placement securities purchase agreements with accredited investors pursuant to which the Company agreed to issue up to 9,400,000 0.0025 23,500 On December 16, 2014, pursuant to a conversion notice, $ 6,000 0.0012 5,194,805 On December 24, 2014, pursuant to a conversion notice, $ 3,762 0.0007 5,700,000 On December 26, 2014, pursuant to a conversion notice, $ 4,044 0.0007 5,655,958 During the year ended June 30, 2015, pursuant to the January 30, 2015 Settlement and Lock-up Agreement (Note 9), the Company issued 10,000,000 0.0025 25,000 On February 2, 2015, pursuant to a conversion notice, $ 3,446 0.0006 6,265,964 On February 4, 2015, pursuant to debt settlement agreements with two directors (Note 4), the Company issued 17,654,470 33,259,350 0.0025 44,136 83,148 On February 9, 2015, pursuant to a conversion notice, $ 21,100 0.0035 6,089,544 On February 17, 2015, pursuant to a conversion notice, $ 3,266 0.0006 5,937,563 On February 17, 2015, pursuant to a conversion notice, $ 15,323 0.0035 4,422,257 On March 6, 2015, pursuant to a conversion notice, $ 3,410 0.0006 6,200,000 On March 6, 2015, pursuant to a conversion notice, $ 6,443 0.0015 4,338,384 On March 6, 2015, pursuant to a conversion notice, $ 1,011 0.0015 680,485 On March 11, 2015, pursuant to a conversion notice, $ 14,675 0.0015 9,882,013 On March 11, 2015, pursuant to a conversion notice, $ 10,121 0.0015 6,815,185 On March 12, 2015, pursuant to a conversion notice, $ 1,001 0.0015 674,141 On March 12, 2015, pursuant to a conversion notice, $ 14,678 0.0015 9,884,155 On March 12, 2015, pursuant to a conversion notice, $ 10,125 0.0016 6,347,918 On March 16, 2015, pursuant to a conversion notice, $ 15,534 0.0017 9,110,833 On March 17, 2015, pursuant to a conversion notice, $ 1,061 0.0017 622,504 On March 17, 2015, pursuant to a conversion notice, $ 20,048 0.0019 10,414,660 On March 18, 2015, pursuant to a conversion notice, $ 20,053 0.0020 10,127,576 On March 19, 2015, pursuant to a conversion notice, $ 8,260 0.0020 4,171,808 On March 20, 2015, pursuant to a conversion notice, $ 23,762 0.0020 12,001,242 On April 14, 2015, pursuant to a conversion notice, $ 4,271 0.0020 2,135,450 On April 15, 2015, pursuant to a conversion notice, $ 10,145 0.0020 5,072,740 On April 21, 2015, pursuant to a conversion notice, $ 28,202 0.0020 14,100,870 On May 7, 2015, the Company entered into an agreement with a consultant to provide services over a six month period in exchange for 6,758,316 shares of common stock. The Company valued the 6,758,316 0.043 290,608 6,758,316 88,446 On May 21, 2015, the Company entered into an agreement with a consultant to provide services over an eight month period in exchange for 1,000,000 shares of common stock. The Company valued the 1,000,000 0.0445 44,500 1,000,000 7,265 On June 4, 2015, the Company entered into an agreement with a consultant to provide services over a six month period in exchange for 500,000 shares of common stock. The Company valued the 500,000 0.0706 35,300 500,000 5,015 Warrants: In September, 2013, pursuant to convertible debenture, the Company issued 3,000,000 0.0698 5 In connection with above agreement dated May 7, 2015, the Company issued to the consultant, warrants for 3,379,158 0.043 0.03 397 60 1.54 145,303 101,080 44,223 In connection with above agreement dated May 21, 2015, the Company issued to the consultant warrants for 1,000,000 0.0445 0.07 397 60 1.54 44,500 37,235 7,265 As of June 30, 2015, there were 7,379,158 Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2013 - $ - Issued 3,000,000 0.07 Exercised - - Expired - - Outstanding at June 30, 2014 3,000,000 0.07 Issued 4,379,158 0.04 Exercised - - Expired - - Outstanding at June 30, 2015 7,379,158 $ 0.05 Exercisable at June 30, 2015 7,379,158 $ 0.05 Outstanding and Exercisable: Weighted average remaining contractual term 4.21 Aggregate intrinsic value $ 319,774

COMMITMENTS AND CONTINGIENCIES

COMMITMENTS AND CONTINGIENCIES	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 – COMMITMENTS AND CONTINGIENCIES Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. The Company is presently in litigation with JMJ Financial Inc., a Florida corporation (“JMJ”), in the Circuit Court of Dade County, Florida. JMJ is claiming funds due under a convertible promissory note of Twenty Five thousand Dollars ($25,000.00). The Company is actively defending all allegations made by JMJ, and has lodged a counter claim against the plaintiff. The parties are currently negotiating for a possible settlement, and a mediation is expected to be scheduled in September or October 201 to determine a settlement. The Company does not believe the result of this litigation matter will have a material adverse effect on our financial conditions or results of operations. Operating Agreements In November 2009, the Company entered into a commercialization agreement whereby the Company agreed to pay royalties of 2 5 Operating Leases From July 2013 through April 30, 2015, the Company utilized office space at a certain location. There was no formal lease agreement and no amounts were paid, but the Company had accrued a liability as of April 30, 2015 of approximately $ 21,000 1,000 2,200 Rent expense for the years ended June 30, 2015 and 2014 were $ 3,719 11,016 Settlement and Stipulation Agreement In July 2014, the Company signed a term sheet and a Settlement and Stipulation Agreement (the "Settlement Agreement") with a third party purchaser (the "purchaser") to have that purchaser acquire certain portions of the Company’s liabilities to creditors (“Creditors”) in exchange for an obligation of the Company to issue shares of common stock to the purchaser, which shares of common stock would then be sold by the purchaser and 65 Under the terms of the Settlement Agreement, the variable quantity of common stock will be issued in tranches such that the purchaser would not own more than 9.99 Under the above agreements, in May 2014 the Company also paid an expense fee of $ 25,000 The purchaser entered into agreements through July 2014 with the Creditors to acquire $ 627,998 50,000 75 1,033,000 405,000 During the year ended June 30, 2015, the Company issued a total of 15,587,000 15,587,000 52,907 575,000 310,000 67,000 Equity Purchase Agreement On July 18, 2014 the Company executed an Equity Purchase Agreement (the "agreement") with an investor (the "investor") affiliated with the above purchaser. The Company may sell (put shares) from time to time, during the commitment period discussed below, up to $ 5,000,000 90 9.99 The commitment period is the earlier of the sale of $5,000,000 worth of shares or 24 On July 18, 2014, Company entered into a Registration Rights Agreement with the investor. Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to file a registration statement (the “Registration Statement”) with the SEC to cover the Registrable Securities within one hundred twenty (120) days of closing of an equity purchase. The Company must use its commercially reasonable efforts to cause the Registration Statement relating to the Registered Securities to become effective within five (5) business days after notice from the SEC that such Registration Statement may be declared effective, and keep the Registration Statement effective at all time prior to the termination of the Equity Purchase Agreement until the earliest of (i) date that is three months after the completion of the last Closing date (as defined in the Equity Purchase Agreement), (ii) the date when the investor may sell all Registered Securities under Rule 144 without volume limitations, or (iii) the date the investor no longer owns any of the Registered Securities (collectively, the “Registration Period”). On July 18, 2014 the Company paid a $ 50,000 50,000 10,000,000 50,000 25,000 1,466 0.0025 25,000 51,466

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 10 – RELATED PARTY TRANSACTIONS Since inception, Propanc Health Group Corporation has conducted transactions with directors and director related entities. These transactions included the following: As of June 30, 2015 and June 30, 2014, the Company owed certain directors a total of $ 79,416 161,975 As of June 30, 2015 and June 30 2014, the Company owed two directors a total of $ 35,108 60,350 On February 4, 2015, the Company entered into a Debt Settlement Agreement with some of these directors whereby the Company issued 33,259,350 17,654,470 41,000 0.0025 127,284 86,455

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	12 Months Ended
	Jun. 30, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 11 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through June 30, 2015. Receivable Concentration As of June 30, 2015 and 2014, the Company’s receivables were 100 Product and Patent Concentration As of June 30, 2015 the Company was undertaking preclinical activities for their lead product. The Company was also undertaking research to uncover the mechanism of action of their lead product in order to screen new compounds for development. The Company previously expanded by the filing of an international PCT patent application (No. PCT/AU2010/001403) directed to enhanced proenzyme formulations and combination therapies. The international PCT application has been based on previous provisional patent applications capturing the Company’s ongoing research and development in this area. The Company received grant status in South Africa and more recently in Australia and New Zealand. In addition, the United States Patent and Trademark Office or USPTO and European Patent Office or EPO have made preliminary indications that key features of our technology are patentable. The Company is presently working towards securing a patent in each region, covering as many aspects of its technology as possible, while also actively seeking protection throughout Eastern Europe, Asia and South America. Individual countries and regions, include United States, Canada, Japan, Brazil, China, Mexico, Hong Kong, Singapore, Israel, Chile, Peru, Malaysia, Vietnam, Indonesia, Europe, Russia, India, and South Korea. The patent is granted in South Africa, Australia, and New Zealand. Further provisional patent filings are also expected to be filed to capture and protect additional patentable subject matter that is identified, namely further enhanced formulations, combination treatments, use of recombinant products, modes of action and molecular targets. Foreign Operations As of June 30, 2015 and 2014, the Company's operations are based in Australia.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS	12 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 12 - DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC Topic 815-40, Contracts in Entity’s Own Equity 3,000,000 335,000 87,500 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Black Scholes (“BSM”) option pricing model. The closing price of the Company’s common stock at June 30, 2015 was $ 0.0899 Initial Valuation September 30, 2013 June 30, 2014 June 30, 2015 Volatility 53 % 134 % 408 % Expected remaining term 5 4.25 3.25 Risk-free interest rate 0.4 % 0.47 % 1.63 % Expected dividend yield None None None Convertible Debt Initial Valuations June 30, 2015 Volatility 216 - 377 % 408 % Expected remaining term 0.83 – 2.00 0.82 – 1.70 Risk-free interest rate 0.5 – 0.7 % 0.64 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the BSM option pricing model. Balance at Quoted Prices Significant June in Active Other Significant 30, Markets for Observable Unobservable 2015 Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 780,281 $ — $ — $ 780,281 Fair value of liability for warrant derivative instruments $ 269,648 $ — $ — $ 269,648 Total $ 1,049,929 $ — $ — $ 1,049,929 Balance at Quoted Prices Significant June in Active Other Significant 30, Markets for Observable Unobservable 2014 Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Fair value of liability for warrant derivative instruments $ 158,244 $ — $ — $ 158,244 Fair Value of Liability for Derivative Instruments Balance at June 30, 2013 $ - Effects of foreign currency exchange rate changes (2,519) Initial fair value of embedded conversion option derivative liability recorded as debt discount 144,241 Change in fair value included in statements of operations 16,522 Balance at June 30, 2014 158,244 Effects of foreign currency exchange rate changes (42,796) Initial fair value of embedded conversion option derivative liability recorded as debt discount 392,500 Initial fair value of embedded conversion option derivative liability recorded as change in fair value of ECO 1,082,567 Change in fair value included in statements of operations (540,586) Balance at June 30, 2015 $ 1,049,929

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS Subsequent to June 30, 2015, the Company received payment of the Secured Investor Note of $ 220,000 20,000 1,997 201,997 0.07 (See Note 6). On July 14, 2015, the Company received payment of three Note Receivables of $ 352,500 17,690 334,810 (See Note 6). On July 15, 2015, the Company paid cash of $ 137,915 104,000 2,872 31,043 On August 14, 2015, pursuant to a conversion notice, $ 20,500 0.02365 866,796 On August 14, 2015, pursuant to a conversion notice, $ 20,802 0.02365 879,585 On August 26, 2015, pursuant to a conversion notice, $ 26,068 0.018425 1,414,843 On August 26, 2015, the Company issued 560,000 0.04 On September 1, 2015, pursuant to a conversion notice, $ 25,723 0.018425 1,396,108 On September 4, 2015, pursuant to a conversion notice, $ 15,648 0.018425 849,263 On September 8, 2015, the Company issued 600,000 0.0369 On September 16, 2015, pursuant to a conversion notice, $ 15,687 0.018975 826,726 On September 18, 2015, pursuant to a conversion notice, $ 15,694 0.017875 877,969 On September 22, 2015, pursuant to a conversion notice, $ 15,638 0.01716 911,294 On September 24, 2015 1,200,000 1,200,000 The debenture has a maturity date of the earlier of: (i) the date on which the Company closes a subsequent equity offering in an amount greater than the principal amount of the Note; or (ii) June 24, 2016. th 180,000 0.0346 20

NATURE OF OPERATIONS AND SUMM20

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Nature of Operations, Policy [Policy Text Block]	Nature of Operations Propanc PTY LTD was incorporated in Melbourne, Victoria Australia on October 15, 2007, and is based in Richmond, Victoria Australia. Since inception, substantially all of the efforts of the Company have been the development of new cancer treatments targeting high risk patients who need a follow up, nontoxic, long term therapy which prevents the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. On November 23, 2010, Propanc Health Group Corporation ("the Company", "we", "us", "our") was incorporated in the state of Delaware. In January 2011, to reorganize the Company, Propanc Health Group Corporation acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary.
Consolidation, Policy [Policy Text Block]	Principals of Consolidation The consolidated financial statements include the accounts of Propanc Health Group Corporation and its wholly-owned subsidiary, Propanc PTY LTD. All significant inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation and Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollars ($) and/or USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss as other income (expense). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Comprehensive income (loss) for all periods presented, includes only foreign currency translation gains (losses). Foreign Currency Items: Beginning balance, June 30, 2013 $ (244,589) Foreign currency translation loss (58,274) Balance, June 30, 2014 (302,863) Foreign currency translation gain 403,831 Ending balance, June 30, 2015 $ 100,968
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Fair Value Measurements The Company measures their financial assets and liabilities in accordance with US GAAP. For certain of the Company’s financial instruments, including cash and cash equivalents, accounts and other receivables, accounts payable and accrued expenses and other liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for loans payable, also approximate fair value because current interest rates available to us for debt with similar terms and maturities are substantially the same. The Company adopted accounting guidance for fair value measurements of financial assets and liabilities. The adoption did not have a material impact on the Company’s results of operations, financial position or liquidity. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of June 30, 2015 or 2014.
Receivables, Policy [Policy Text Block]	Receivables As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of uncollectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis included the age of the receivable account, creditworthiness of the customer and general economic conditions.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant, and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: Machinery and equipment 5
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Patents Patent costs are stated at cost and reclassified to intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency, however, the Company will expense any costs as long as the Company is in the startup stage. Accordingly, as the Company's product was and is not currently approved for market, thus any patent costs incurred from 2013 through 2015 were expensed immediately. Currently, the Company has one International patent pending which was jointly applied for by the Company and another entity. The Company received grant status , or been accepted in South Africa, Australia, and New Zealand. In addition, the United States Patent and Trademark Office or USPTO and European Patent Office or EPO have made preliminary indications that key features of the Company’s technology are patentable. The Company is presently working towards securing a patent in each region, covering as many aspects of its technology as possible, whilst also actively seeking protection throughout Eastern Europe, Asia and South America. Individual countries and regions where the Company is actively seeking patent protection include United States, Canada, Japan, Brazil, China, Mexico, Hong Kong, Singapore, Israel, Chile, Peru, Malaysia, Vietnam, Indonesia, Europe, Russia, India, and South Korea. The patent is now granted , or accepted in South Africa, Australia, and New Zealand.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Compensation Related Costs, Policy [Policy Text Block]	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, annual leave, accumulated sick leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months and therefore, recorded at nominal value.
Goods And Service Tax [Policy Text Block]	Australian Goods and Services Tax (GST) Revenues, expenses and balance sheet items are recognized net of the amount of GST except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2015 and June 30, 2014 the Company was owed $ 11,647 946
Derivatives, Policy [Policy Text Block]	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes [Policy Text Block]	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480 and measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion, and records the put premium as accretion to interest expense to the date of first conversion.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. The Company adopted provisions of ASC 740, Sections 25 through 60, “Accounting for Uncertainty in Income Taxes." These sections provide detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of ASC 740 and in subsequent periods. Upon the adoption of ASC 740, the Company had no unrecognized tax benefits. During the years ended June 30, 2015 and 2014 no adjustments were recognized for uncertain tax benefits. The years 2008 through 2015 are subject to examination by the Australian Taxation Office. The years ended June 30, 2012 through 2015 is subject to examination by the United States Internal Revenue Service.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs and Tax Credits In accordance with ASC 730-10, research and development costs are expensed when incurred. Total research and development costs for the years ended June 30, 2015 and 2014 were $ 134,319 8,168 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income then the Company can receive the credit which reduces its income tax liability. If the Company has net losses then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During the years ended June 30, 2015 and 2014, the Company applied for and received from the Australian Taxation Office a research and development tax credit in the amount of $ 77,470 48,267
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company records stock based compensation in accordance with ASC section 718, “Stock Compensation” and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “Equity-Based Payments to Non-Employees”.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition In accordance with SEC Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition, (codified in ASC 605) the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists or acceptance occurs, (ii) a retailer, distributor or wholesaler receives the goods, (iii) the price is fixed or determinable, and (iv) collectability of the sales revenues is reasonably assured. Subject to these criteria, the Company recognizes revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.
Start-up Activities, Cost Policy [Policy Text Block]	Start-up Costs In accordance with ASC 720-15-15, start-up costs are expensed as incurred.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. For the years ended June 30 2015 and 2014, there were 7,379,158 3,000,000 335,716,597 6,069,667
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements Financial Accounting Standards Board, Accounting Standard Updates which are not effective until after June 30, 2015 are not expected to have a significant effect on the Company’s consolidated financial position or results of operations. The Company implemented the following at June 30, 2015: In June 2014, the FASB issued ASU No. 2014-10, which amended Accounting Standards Codification (ASC) Topic 915 Development Stage Entities. The amendment eliminates certain financial reporting requirements surrounding development stage entities, including an amendment to the variable interest entities guidance in ASC Topic 810, Consolidation. The amendment removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other entities from U.S. GAAP. Consequently, the amendment eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This amendment is effective for fiscal years beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has made the election to early adopt this amendment effective June 30, 2014 and, as a result, the Company is no longer presenting or disclosing the information previously required under Topic 915. The early adoption was made to reduce data maintenance by removing all incremental financial reporting requirements for development stage entities. The adoption of this amendment alters the disclosure requirements of the Company, but it does not have any material impact on the Company's financial position or results of operations for the current or any prior reporting periods. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements – Going Concern (Topic 205-40)”, which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period. If substantial doubt exists, additional disclosure is required. This new standard will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to adopt this new standard as of December 31, 2015. The Company does not expect this ASU to have a material impact on its consolidated financial statements. On May 8, 2015, the FASB issued ASU 2015-08, “Business Combinations (Topic 805) Pushdown Accounting ” which conforms the FASB’s guidance on pushdown accounting with the SEC’s guidance. ASU 2015-08 is effective for annual periods beginning after December 15, 2015. The Company does not expect this ASU to have a material impact on its consolidated financial statements. In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs," which changes the presentation of debt issuance costs in financial statements. Under this guidance such costs would be presented as a direct deduction from the related debt liability rather than as an asset. This guidance is effective for interim and annual reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its Consolidated Balance Sheet, but expects that as of June 30, 2015 this guidance would not have a material effect on the consolidated balances current presentation.

NATURE OF OPERATIONS AND SUMM21

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2015 and 2014 were as follows: Foreign Currency Items: Beginning balance, June 30, 2013 $ (244,589) Foreign currency translation loss (58,274) Balance, June 30, 2014 (302,863) Foreign currency translation gain 403,831 Ending balance, June 30, 2015 $ 100,968

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant, and equipment consist of the following as of June 30, 2015 2014 Office equipment at cost $ 15,732 $ 14,968 Less: Accumulated depreciation (12,238) (14,968) Total property, plant, and equipment $ 3,494 $ -

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of convertible debenture [Table Text Block]	Convertible notes at June 30, 2015 and 2014 were as follows: June 30, 2015 June 30, 2014 Convertible notes and debenture $ 1,455,000 $ 366,296 Unamortized discounts (415,467) (121,059) Accrued interest 26,989 - Premium, net 727,853 27,187 Convertible notes, net $ 1,794,375 $ 272,424

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components for the provision for income taxes are as follows: Year Ended June 30, June 30, 2015 2014 Current Taxes $ (77,470) $ (48,267) Deferred Taxes - - Income Taxes Expense (Benefit) $ (77,470) $ (48,267)
Schedule Of Differences Between Income Taxes And Provision For Income Taxes [Table Text Block]	The items accounting for the difference between income taxes at the Australia statutory rate and the provision for income taxes are as follows: Year Ended June 30, June 30, 2015 2014 Impact on Impact on Amount Rate Amount Rate Income Tax Expense (Benefit) at Australia Statutory Rate $ (672,087) (19.26) % $ (274,229) (31.24) % Expenses Paid by Parent on Behalf of Foreign Subsidiary 156,410 4.48 % 92,480 10.54 % R&D Refundable Tax Credit (77,470) (2.22) % (48,267) (5.50) % Reduction of NOL Carryforward Due to R&D Tax Credit 77,470 2.22 % 48,267 5.50 % Change in Deferred Tax Valuation Allowance (355,636) (10.19) % 260,533 29.68 % Foreign Exchange Rate Changes 793,843 22.74 % (127,051) (14.47) % Total Income Tax Expense (Benefit) $ (77,470) (2.22) % $ (48,267) (5.50) %
Schedule Of Deferred Income Taxes [Table Text Block]	Significant components of the Company's net deferred income taxes are as follows: June 30, June 30, 2015 2014 Current Deferred Tax Assets Warrant Derivative Liability $ 88,204 $ 28,209 Provision for Annual Leave 21,426 18,848 Superannuation - 3,815 Total Current Deferred Tax Assets $ 109,630 $ 50,872 Current Deferred Tax Liabilities Prepaid Investor Services $ - $ - Prepaid Expenses - - Prepaid Insurance - - Accounts Payable/Trade Creditors - - Patent Costs - - Total Current Deferred Tax Liabilities $ - $ - Non-Current Deferred Tax Assets Prepaid Investor Services $ 185,025 $ 751,917 Capital Raising Costs 23,261 28,622 Legal Costs 23,583 29,019 Intellectual Property 11,612 14,288 Patent Costs 59,995 59,473 Formation Expense 7,117 8,757 Net Operating Loss Carryover 3,426,149 3,259,060 Foreign Exchange Loss (OCI) (30,290) 90,859 Total Non-Current Deferred Tax Assets 3,706,452 4,241,995 Deferred Tax Valuation Allowance (3,816,082) (4,292,867) Total Non-Current Deferred Tax Assets (109,630) (50,872) Total Deferred Tax Assets (Net) $ - $ -

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes warrant activity for the years ended June 30, 2015 and 2014: Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2013 - $ - Issued 3,000,000 0.07 Exercised - - Expired - - Outstanding at June 30, 2014 3,000,000 0.07 Issued 4,379,158 0.04 Exercised - - Expired - - Outstanding at June 30, 2015 7,379,158 $ 0.05 Exercisable at June 30, 2015 7,379,158 $ 0.05 Outstanding and Exercisable: Weighted average remaining contractual term 4.21 Aggregate intrinsic value $ 319,774

DERIVATIVE FINANCIAL INSTRUME26

DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jun. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Warrants Initial Valuation September 30, 2013 June 30, 2014 June 30, 2015 Volatility 53 % 134 % 408 % Expected remaining term 5 4.25 3.25 Risk-free interest rate 0.4 % 0.47 % 1.63 % Expected dividend yield None None None Convertible Debt Initial Valuations June 30, 2015 Volatility 216 - 377 % 408 % Expected remaining term 0.83 – 2.00 0.82 – 1.70 Risk-free interest rate 0.5 – 0.7 % 0.64 % Expected dividend yield None None
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2015 and 2014: Balance at Quoted Prices Significant June in Active Other Significant 30, Markets for Observable Unobservable 2015 Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 780,281 $ — $ — $ 780,281 Fair value of liability for warrant derivative instruments $ 269,648 $ — $ — $ 269,648 Total $ 1,049,929 $ — $ — $ 1,049,929 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2014: Balance at Quoted Prices Significant June in Active Other Significant 30, Markets for Observable Unobservable 2014 Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Fair value of liability for warrant derivative instruments $ 158,244 $ — $ — $ 158,244
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	The following is a roll forward for the years ended June 30, 2015 and 2014 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2013 $ - Effects of foreign currency exchange rate changes (2,519) Initial fair value of embedded conversion option derivative liability recorded as debt discount 144,241 Change in fair value included in statements of operations 16,522 Balance at June 30, 2014 158,244 Effects of foreign currency exchange rate changes (42,796) Initial fair value of embedded conversion option derivative liability recorded as debt discount 392,500 Initial fair value of embedded conversion option derivative liability recorded as change in fair value of ECO 1,082,567 Change in fair value included in statements of operations (540,586) Balance at June 30, 2015 $ 1,049,929

NATURE OF OPERATIONS AND SUMM27

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ (302,863)	$ (244,589)
Foreign currency translation gain/loss	403,831	(58,274)
Ending balance	$ 100,968	$ (302,863)

NATURE OF OPERATIONS AND SUMM28

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
GST tax receivable	$ 11,647	$ 946
Income Tax Expense (Benefit)	77,470	48,267
Research and development	$ 134,319	$ 8,168
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	335,716,597	6,069,667
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,379,158	3,000,000
Machinery and Equipment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

GOING CONCERN (Details Textual)

GOING CONCERN (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Going Concern [Line Items]
Net loss	$ (3,412,754)	$ (829,564)
Net Cash Used In Operating Activities	1,426,479	226,442
Stockholders Equity	(3,053,516)	(1,408,314)	$ (792,476)
Working Capital Deficit	3,058,694
Retained Earnings (Accumulated Deficit)	$ (20,965,671)	$ (17,552,917)

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Office equipment at cost	$ 15,732	$ 14,968
Less: Accumulated depreciation	(12,238)	(14,968)
Total property, plant, and equipment	$ 3,494	$ 0

PROPERTY AND EQUIPMENT (Detai31

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 81	$ 538

DUE TO DIRECTORS - RELATED PA32

DUE TO DIRECTORS - RELATED PARTIES (Details Textual) - USD ($)	Feb. 04, 2015	Jul. 02, 2014	Jun. 30, 2015	Jun. 30, 2014	Jan. 30, 2015
Related Party Transaction [Line Items]
Due to Related Parties, Current			$ 35,108	$ 60,350
Decrease In Liability Due To Director			44,000
Increase In The Liability Part Of Settlement Agreement					$ 44,000
Debt Conversion, Converted Instrument, Amount		$ 139,680	$ 152,285	$ 0
Director [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 14,000

LOANS AND NOTES PAYABLE (Detail

LOANS AND NOTES PAYABLE (Details Textual) - USD ($)

Feb. 04, 2015

Jul. 02, 2014

Jan. 30, 2015

Nov. 04, 2014

Sep. 11, 2014

Jul. 18, 2014

May. 31, 2014

Sep. 30, 2013

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2013

Jul. 31, 2014

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Conversion, Converted Instrument, Amount

$ 139,680

$ 152,285

$ 0

Decrease In Liability Due To Director

44,000

Notes Payable, Current

27,558

33,909

Debt Conversion, Converted Instrument, Shares Issued

2,183,333

Debt Conversion, Original Debt, Amount

$ 50,000

Debt Instrument, Convertible, Conversion Price

$ 0.0709

Increase In The Liability Part Of Settlement Agreement

$ 44,000

Conversion of Stock, Amount Converted

71,370

0

Other Liabilities

575,000

Other Long-term Debt, Current

33,909

Payments for Loans

$ 28,455

45,512

Loans from Directors [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Conversion, Converted Instrument, Amount

$ 27,000

Debt Conversion, Converted Instrument, Shares Issued

33,259,350

Settlement And Lock Up Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Other Liabilities

575,000

Settlement And Lock Up Agreement [Member] | Loans from Directors [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Increase In The Liability Part Of Settlement Agreement

109,000

Settlement Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

8,161,000

7,426,000

Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments

$ 81,396

Promissory Note [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Conversion, Converted Instrument, Amount

50,000

Debt Conversion, Original Debt, Amount

$ 25,000

Debt Instrument, Convertible, Conversion Price

$ 0.0025

Gain Or Loss On Debt Conversion Original Debt

$ 51,466

Conversion of Stock, Amount Converted

25,000

25,000

Gains (Losses) on Extinguishment of Debt

51,466

Interest Payable

$ 1,466

Promissory Note [Member] | Settlement And Lock Up Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Conversion, Converted Instrument, Shares Issued

10,000,000

Debt Conversion, Original Debt, Amount

$ 50,000

Promissory Note [Member] | Settlement Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Interest Payable

$ 1,466

Lender [Member] | Settlement Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Instrument, Unamortized Premium

17,000

Debt Instrument, Face Amount

50,000

Gains (Losses) on Extinguishment of Debt

$ 310,000

Non-Interest Bearing [Member] | Investor [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Instrument, Fee Amount

50,000

Non-Interest Bearing [Member] | Promissory Note [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Instrument, Fee Amount

$ 50,000

Two unrelated parties [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Long-term Debt, Gross

$ 33,614

Debt Instrument, Interest Rate During Period

10.00%

Debt Conversion, Converted Instrument, Amount

$ 27,963

unrelated parties [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Long-term Debt, Gross

$ 9,419

Debt Instrument, Interest Rate During Period

10.00%

Notes Payable, Current

27,558

unrelated parties [Member] | Settlement Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Notes Payable, Current

$ 33,909

unrelated parties [Member] | Lender [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Instrument, Fee Amount

$ 50,000

Notes Payable, Current

1,033,000

Debt Instrument, Unamortized Premium

355,000

Debt Instrument, Face Amount

$ 628,000

unrelated parties [Member] | Non-Interest Bearing [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Long-term Debt, Gross

18,839

Directors and Officer [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Long-term Debt, Gross

79,416

$ 161,975

Director [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Conversion, Converted Instrument, Amount

$ 14,000

Debt Conversion, Converted Instrument, Shares Issued

17,654,470

Director [Member] | Loans from Directors [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Debt Conversion, Converted Instrument, Amount

$ 41,000

Debt Instrument, Convertible, Conversion Price

$ 0.0025

Gain Or Loss On Debt Conversion Original Debt

$ 86,455

Conversion of Stock, Amount Converted

127,284

Gains (Losses) on Extinguishment of Debt

$ 86,455

Director [Member] | Settlement Agreement [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Decrease In Liability Due To Director

$ 127,000

CONVERTIBLE NOTES (Details)

CONVERTIBLE NOTES (Details) - Convertible Notes Payable [Member] - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Debt Instrument [Line Items]
Convertible notes and debenture	$ 1,455,000	$ 366,296
Unamortized discounts	(415,467)	(121,059)
Accrued interest	26,989	0
Premium, net	727,853	27,187
Convertible notes, net	$ 1,794,375	$ 272,424

CONVERTIBLE NOTES (Details Text

CONVERTIBLE NOTES (Details Textual)	Jul. 15, 2015USD ($)	Dec. 10, 2014USD ($)	Jul. 02, 2014USD ($)$ / sharesshares	May. 19, 2015	Mar. 12, 2015USD ($)	Feb. 20, 2015USD ($)	Jan. 30, 2015USD ($)	Nov. 17, 2014USD ($)	Aug. 06, 2014USD ($)$ / shares	May. 30, 2014USD ($)	May. 29, 2014USD ($)	Sep. 30, 2013USD ($)$ / sharesshares	Sep. 30, 2013USD ($)$ / shares	Jun. 30, 2015USD ($)$ / shares	Jun. 30, 2014USD ($)	Jun. 30, 2013USD ($)	Jul. 02, 2014AUD / shares	May. 08, 2014USD ($)	Sep. 30, 2013AUDAUD / shares
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 0.0709
Share Price | $ / shares														$ 0.0899
DerivativeLiabilities														$ 1,049,929	$ 158,244	$ 0
Discounts related to warrants issued with convertible debenture														$ 0	$ 133,095
Debt Instrument, Periodic Payment			$ 154,798
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				55.00%
August 2013 Notes [Member]
Debt Instrument [Line Items]
Notes Payable												$ 63,196	$ 63,196
September 2013 Notes [Member]
Debt Instrument [Line Items]
Notes Payable												46,446	$ 46,446
Warrant [Member]
Debt Instrument [Line Items]
Fair Value Assumptions, Expected Volatility Rate													53.00%	408.00%	134.00%
Fair Value Assumptions, Expected Term													5 years	3 years 3 months	4 years 3 months
Fair Value Assumptions, Risk Free Interest Rate													0.40%	1.63%	0.47%
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount							$ 25,000		$ 250,000			$ 139,680	$ 139,680					$ 25,000	AUD 150,000
Debt Instrument, Interest Rate, Stated Percentage												12.00%	12.00%					10.00%	12.00%
Debt Instrument, Convertible, If-converted Value in Excess of Principal																$ 27,963
Debt Instrument, Increase, Accrued Interest			$ 15,118				$ 1,466							$ 2,134
Debt Instrument, Convertible, Conversion Price | (per share)			$ 0.0709														AUD 0.075		AUD 0.075
Debt Instrument, Unamortized Discount									$ 25,000
Stock Issued During Period, Shares, New Issues | shares			2,183,333
Debt Instrument, Debt Default, Interest Rate										16.00%
Discounts related to warrants issued with convertible debenture			$ 139,680
Percentage of Consideration Received									10.00%
Interest Rate on Payment of Consideration									0.00%
Debt Instrument, Interest Rate During Period									12.00%
Debt Instrument, Periodic Payment														$ 25,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger									60.00%					12.00%
Debt Instrument, Convertible, Stock Price Trigger | $ / shares									$ 0.09
Interest Payable														$ 250,000
Convertible Notes Payable [Member] | Warrant [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares												3,000,000
Debt Instrument, Convertible, Conversion Price | (per share)												$ 0.0698	$ 0.0698						AUD 0.075
Share Price | $ / shares												$ 0.20	$ 0.20
Fair Value Assumptions, Expected Volatility Rate												53.00%
Fair Value Assumptions, Expected Term												27 months
Fair Value Assumptions, Risk Free Interest Rate												0.40%
Debt Instrument, Unamortized Discount												$ 400,000	$ 400,000
DerivativeLiabilities												140,000	$ 140,000
Increase Decrease In Derivative Liabilities												$ 260,000
Convertible Notes Payable One [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 75,000			60,453
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Maturity Date											May 29, 2015
Debt Instrument, Unamortized Discount											$ 61,364
Debt Instrument, Convertible, Threshold Trading Days											180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger											55.00%
Interest and Debt Expense														51,089	$ 10,275
Debt Instrument, Periodic Payment, Principal														14,547
Debt Instrument, Periodic Payment, Interest														218
Additionally Debt Instrument Unamortized Premium														61,364
Convertible Notes Payable One [Member] | Third Party [Member]
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest														4,352
Convertible Notes Payable Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 75,000			63,245
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Maturity Date											May 29, 2015
Debt Instrument, Unamortized Discount											$ 61,364
Debt Instrument, Convertible, Threshold Trading Days											180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger											55.00%
Interest and Debt Expense														51,089	10,275
Debt Instrument, Periodic Payment, Principal														11,755
Debt Instrument, Periodic Payment, Interest														553
Additionally Debt Instrument Unamortized Premium														61,364
Convertible Notes Payable Two [Member] | Third Party [Member]
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest														3,313
Convertible Notes Payable Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 50,000
Debt Instrument, Interest Rate, Stated Percentage										8.00%
Debt Instrument, Maturity Date										May 30, 2015
Debt Instrument, Unamortized Discount										$ 40,909
Debt Instrument, Convertible, Threshold Trading Days										180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger										55.00%
Interest and Debt Expense														34,273	$ 6,636
Debt Instrument, Periodic Payment, Principal														50,000
Debt Instrument, Periodic Payment, Interest														3,346
Additionally Debt Instrument Unamortized Premium														40,909
Convertible Notes Payable Four [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount								$ 43,000
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Debt Instrument, Maturity Date								Aug. 20, 2015
Debt Instrument, Unamortized Discount								$ 31,138
Debt Instrument, Convertible, Threshold Trading Days								180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger								58.00%
Debt Instrument, Periodic Payment, Principal														27,851
Debt Instrument, Periodic Payment, Interest														1,527
Repayments of Debt														61,632
Debt Instrument, Annual Principal Payment														43,000
Prepayment Penalties														17,105
Debt Instrument, Increase (Decrease), Other, Net														3,287
Convertible Notes Payable Five [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 28,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Maturity Date		Sep. 12, 2015
Debt Instrument, Increase, Accrued Interest														853
Debt Instrument, Unamortized Discount		$ 20,276
Debt Instrument, Convertible, Threshold Trading Days		180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		58.00%
Debt Instrument, Periodic Payment, Principal														15,657
Repayments of Debt														38,654
Debt Instrument, Annual Principal Payment														28,000
Prepayment Penalties														9,801
Debt Instrument, Increase (Decrease), Other, Net														4,619
Convertible Back-End Notes Payable One [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 75,000
Debt Instrument, Percentage of Repayment, If prepaid within 60 days of the issuance date										130.00%
Debt Instrument, Percentage of Repayment, if prepaid 60 but less than 121 days after the issuance date										140.00%
Debt Instrument, Percentage of Repayment, if prepaid 120 but less than 180 days after the issuance date										150.00%
Convertible Back-End Notes Payable Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 75,000
Convertible Back-End Notes Payable Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 50,000
Convertible Note Payable Eight [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 104,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Debt Instrument, Maturity Date					Dec. 16, 2015
Debt Instrument, Increase, Accrued Interest														2,530
Debt Instrument, Unamortized Premium					$ 75,310									46,441
Debt Instrument, Convertible, Threshold Trading Days					180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger					58.00%
Debt Instrument, Periodic Payment, Interest	$ 2,872
Repayments of Debt	137,915
Debt Instrument, Annual Principal Payment	$ 104,000
Convertible Note Payable Seven [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 58,000
Debt Instrument, Interest Rate, Stated Percentage						12.00%
Debt Instrument, Maturity Date						Jul. 27, 2015
Debt Instrument, Unamortized Premium						$ 58,000								36,411
Debt Instrument, Convertible, Threshold Trading Days						180
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger						50.00%
Debt Instrument, Periodic Payment, Interest														2,212
Repayments of Debt														83,512
Debt Instrument, Annual Principal Payment														58,000
Prepayment Penalties														23,300
Debt Instrument, Increase (Decrease), Other, Net														$ 21,589

CONVERTIBLE NOTES (Details Te36

CONVERTIBLE NOTES (Details Textual 1)

Jul. 15, 2015USD ($)

Jun. 04, 2015USD ($)$ / shares

Jul. 02, 2014USD ($)$ / shares

Jun. 02, 2015USD ($)

May. 19, 2015USD ($)

Apr. 27, 2015USD ($)

Apr. 24, 2015USD ($)

Apr. 20, 2015USD ($)

Mar. 20, 2015USD ($)

Mar. 12, 2015USD ($)$ / shares

Feb. 20, 2015USD ($)

Feb. 17, 2015USD ($)

Feb. 15, 2015USD ($)

Feb. 10, 2015USD ($)

Jan. 27, 2015USD ($)

Jan. 26, 2015USD ($)

Jul. 18, 2014USD ($)

Jun. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Debt Instrument [Line Items]

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Proceeds from Notes Payable

$ 50,000

Noninterest Expense Transfer Agent and Custodian Fees

7,779

Legal Fees

2,500

Expense Related to Distribution or Servicing and Underwriting Fees

5,000

Net Proceeds From Notes Issued

34,721

Amortization of debt discount

$ 295,795

$ 49,029

Debt Conversion, Original Debt, Amount

$ 50,000

Debt Conversion, Converted Instrument, Amount

$ 139,680

152,285

0

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.0709

Convertible Notes Payable

$ 782,500

Six Month Consulting Agreement [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Maturity Date

Aug. 15, 2015

Debt Instrument, Unamortized Premium

$ 60,000

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

60.00%

Debt Instrument, Increase, Accrued Interest

$ 1,677

Debt Conversion, Converted Instrument, Amount

$ 90,000

Two Year Consulting Agreement [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Maturity Date

Mar. 11, 2017

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

75.00%

Debt Conversion, Converted Instrument, Amount

$ 60,000

Interest Payable

1,825

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.0175

Convertible Note Payable [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 1,215,000

Debt Instrument, Unamortized Discount

$ 110,000

529,500

30,000

Debt Instrument, Increase, Accrued Interest

$ 2,513

Debt Instrument, Percentage of Repayment, If prepaid within 60 days of the issuance date

130.00%

Debt Instrument, Percentage of Repayment, if prepaid 60 but less than 121 days after the issuance date

140.00%

Debt Instrument, Percentage of Repayment, if prepaid 120 but less than 180 days after the issuance date

150.00%

Debt Instrument, Debt Default, Interest Rate

24.00%

Amortization of debt discount

$ 114,033

$ 3,133

Percentage of Consideration Received

10.00%

Convertible Note Payable One [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 28,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Oct. 28, 2015

Debt Instrument, Unamortized Premium

$ 20,276

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

58.00%

Debt Instrument, Increase, Accrued Interest

835

Debt Instrument, Periodic Payment, Principal

15,432

Repayments of Debt

37,137

Debt Instrument, Annual Principal Payment

28,000

Prepayment Penalties

8,302

Debt Instrument, Increase (Decrease), Other, Net

4,844

Convertible Note Payable Two [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Premium

$ 40,909

40,909

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Additionally Debt Instrument Unamortized Premium

40,909

Debt Conversion, Original Debt, Amount

50,000

Interest Payable

609

Convertible Note Payable Three [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 45,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Feb. 10, 2016

Debt Instrument, Unamortized Discount

$ 7,500

Debt Instrument, Unamortized Premium

$ 36,818

27,409

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

1,391

Convertible Note Payable Four [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 45,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Feb. 17, 2016

Debt Instrument, Unamortized Discount

$ 7,500

Debt Instrument, Unamortized Premium

$ 36,818

27,409

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

1,322

Convertible Note Payable Five [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 170,500

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Mar. 12, 2016

Debt Instrument, Unamortized Discount

$ 13,000

Debt Instrument, Unamortized Premium

$ 139,500

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

4,148

Convertible Note Payable Six [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Mar. 20, 2016

Debt Instrument, Unamortized Premium

$ 122,727

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

3,386

Convertible Back-End Note Payable One [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

45,000

Convertible Back-End Note Payable Two [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

45,000

Convertible Back-End Note Payable Three [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

170,500

Convertible Back-End Note Payable Four [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

150,000

Convertible Note Payable Seven [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 58,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Maturity Date

Jul. 27, 2015

Debt Instrument, Unamortized Premium

$ 58,000

36,411

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

50.00%

Repayments of Debt

83,512

Debt Instrument, Annual Principal Payment

58,000

Prepayment Penalties

23,300

Debt Instrument, Increase (Decrease), Other, Net

21,589

Debt Instrument, Periodic Payment, Interest

2,212

Convertible Note Payable Eight [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 104,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Dec. 16, 2015

Debt Instrument, Unamortized Premium

$ 75,310

46,441

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

58.00%

Debt Instrument, Increase, Accrued Interest

2,530

Repayments of Debt

$ 137,915

Debt Instrument, Annual Principal Payment

104,000

Debt Instrument, Periodic Payment, Interest

$ 2,872

Convertible Notes Payable Ten [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount

$ 7,500

Debt Instrument, Unamortized Premium

$ 36,818

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

$ 671

Interest and Debt Expense

13,909

Proceeds from Notes Payable

45,000

Legal Fees

2,250

Net Proceeds From Notes Issued

35,250

Convertible Notes Payable Eleven [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount

7,500

Debt Instrument, Unamortized Premium

$ 36,818

Debt Instrument, Convertible, Threshold Trading Days

180

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

671

Interest and Debt Expense

13,909

Proceeds from Notes Payable

$ 45,000

Legal Fees

2,250

Net Proceeds From Notes Issued

$ 35,250

Convertible Notes Payable Twelve [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount

$ 13,000

Debt Instrument, Unamortized Premium

$ 139,500

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

2,429

Proceeds from Notes Payable

$ 170,500

Legal Fees

7,500

Net Proceeds From Notes Issued

$ 150,000

Convertible Promissory Back-End Notes One [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

37,500

Convertible Promissory Back-End Notes Two [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

37,500

Convertible Promissory Back-End Notes Three [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

157,500

Convertible Promissory Back-End Notes Four [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

150,000

Convertible Promissory Back-End Notes Five [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

17,500

Convertible Promissory Back-End Notes Six [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

37,500

Convertible Promissory Back-End Notes Seven [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

37,500

Convertible Promissory Back-End Notes Eight [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

157,500

Convertible Promissory Back-End Notes Nine [Member]

Debt Instrument [Line Items]

Convertible Notes Payable

$ 150,000

Convertible Notes Payable Fourteen [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Premium

$ 122,727

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

2,137

Proceeds from Notes Payable

$ 150,000

Legal Fees

7,500

Net Proceeds From Notes Issued

$ 142,500

Secured Investor Note One [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount

$ 30,000

Legal Fees

5,000

Debt Convertible Note cash Purchase

335,000

Secured Investor Note Two [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount

20,000

Debt Convertible Note cash Purchase

220,000

Secured Investor Note Three [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount

20,000

Debt Convertible Note cash Purchase

$ 220,000

Execution Note [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Unamortized Discount

$ 30,000

Legal Fees

$ 5,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.07

Debt Convertible Note cash Purchase

$ 300,000

Secured Debt, Secured Percentage by Lender

40.00%

Market Capitalization Minimum Amount

$ 3,000,000

Convertible Note Payable Nine [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 17,500

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Apr. 20, 2016

Debt Instrument, Unamortized Premium

$ 14,318

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

55.00%

Debt Instrument, Increase, Accrued Interest

$ 272

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Current Taxes	$ (77,470)	$ (48,267)
Deferred Taxes	0	0
Income Taxes Expense (Benefit)	$ (77,470)	$ (48,267)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Income Tax Expense (Benefit) at Australia Statutory Rate	$ (672,087)	$ (274,229)
Expenses Paid by Parent on Behalf of Foreign Subsidiary	156,410	92,480
R&D Refundable Tax Credit	(77,470)	(48,267)
Reduction of NOL Carryforward Due to R&D Tax Credit	77,470	48,267
Change in Deferred Tax Valuation Allowance	(355,636)	260,533
Foreign Exchange Rate Changes	793,843	(127,051)
Total Income Tax Expense (Benefit)	$ (77,470)	$ (48,267)
Income Tax Expense (Benefit) at Australia Statutory Rate, Impact on Rate	(19.26%)	(31.24%)
Expenses paid by parent on behalf of foreign subsidiary, Impact on Rate	4.48%	10.54%
R&D Refundable Tax Credit, Impact on Rate, Impact on Rate	(2.22%)	(5.50%)
Reduction of NOL Carryforward Due to R&D Tax Credit, Impact on Rate	2.22%	5.50%
Change in deferred Tax Valuation Allowance, Impact on Rate	(10.19%)	29.68%
Foreign Exchange Rate Changes, Impact on Rate	22.74%	(14.47%)
Total Income Tax Expense (Benefit), Impact on Rate	(2.22%)	(5.50%)

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Current Deferred Tax Assets
Total Current Deferred Tax Assets	$ 109,630	$ 50,872
Current Deferred Tax Liabilities
Total Current Deferred Tax Liabilities	0	0
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	3,706,452	4,241,995
Deferred Tax Valuation Allowance	(3,816,082)	(4,292,867)
Total Non-Current Deferred Tax Assets	(109,630)	(50,872)
Total Deferred Tax Assets (Net)	0	0
Warrant Derivative Liability [Member]
Current Deferred Tax Assets
Total Current Deferred Tax Assets	88,204	28,209
Provision For Annual Leave [Member]
Current Deferred Tax Assets
Total Current Deferred Tax Assets	21,426	18,848
Superannuation [Member]
Current Deferred Tax Assets
Total Current Deferred Tax Assets	0	3,815
Prepaid Investor Services [Member]
Current Deferred Tax Liabilities
Total Current Deferred Tax Liabilities	0	0
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	185,025	751,917
Prepaid Expenses [Member]
Current Deferred Tax Liabilities
Total Current Deferred Tax Liabilities	0	0
Prepaid Insurance [Member]
Current Deferred Tax Liabilities
Total Current Deferred Tax Liabilities	0	0
Accounts Payable/Trade Creditors [Member]
Current Deferred Tax Liabilities
Total Current Deferred Tax Liabilities	0	0
Patent Costs [Member]
Current Deferred Tax Liabilities
Total Current Deferred Tax Liabilities	0	0
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	59,995	59,473
Capital Raising Costs [Member]
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	23,261	28,622
Legal Costs [Member]
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	23,583	29,019
Intellectual Property [Member]
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	11,612	14,288
Formation Expense [Member]
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	7,117	8,757
Net Operating Loss Carryover [Member]
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	3,426,149	3,259,060
Foreign Exchange Loss (OCI) [Member]
Non-Current Deferred Tax Assets
Total Non-Current Deferred Tax Assets	$ (30,290)	$ 90,859

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Income (Loss)	$ (1,705,587)	$ (761,221)
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,527,228
Australian Taxation Office [Member]
Operating Income (Loss)	$ 12,486,000

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Number of Shares Outstanding-Beginning Balance (In shares)	3,000,000	0
Number of Shares-Issued	4,379,158	3,000,000
Number of Shares-Exercised	0	0
Number of Shares-Expired	0	0
Number of Shares Outstanding-Ending Balance (In shares)	7,379,158	3,000,000
Number of Shares Exercisable	7,379,158
Outstanding and Exercisable:
Number of Shares-Weighted average remaining contractual term	4 years 2 months 16 days
Number of Shares-Aggregate intrinsic value	$ 319,774
Weighted Average Price pre share-Beginning Balance	$ 0.07	$ 0
Weighted Average Price pre share-Issued	0.04	0.07
Weighted Average Price pre share-Exercised	0	0
Weighted Average Price pre share-Expired	0	0
Weighted Average Price pre share-Ending Balance	0.05	$ 0.07
Weighted Average Price Per Shares Exercisable	$ 0.05

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Textual) - USD ($)	Jul. 02, 2015	Jun. 05, 2015	Jun. 04, 2015	Jun. 03, 2015	May. 07, 2015	Apr. 14, 2015	Mar. 17, 2015	Mar. 16, 2015	Mar. 12, 2015	Mar. 11, 2015	Mar. 06, 2015	Feb. 17, 2015	Feb. 09, 2015	Feb. 04, 2015	Feb. 02, 2015	Dec. 10, 2014	Dec. 09, 2014	Dec. 04, 2014	Nov. 04, 2014	Aug. 07, 2014	Jul. 02, 2014	May. 09, 2014	May. 21, 2015	Apr. 28, 2015	Apr. 21, 2015	Apr. 15, 2015	Mar. 20, 2015	Mar. 19, 2015	Mar. 18, 2015	Jan. 30, 2015	Dec. 26, 2014	Dec. 24, 2014	Dec. 16, 2014	Dec. 11, 2014	Nov. 05, 2014	Oct. 17, 2014	Sep. 11, 2014	Jul. 18, 2014	Nov. 30, 2013	Oct. 31, 2013	Sep. 30, 2013	Jul. 31, 2013	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Jul. 10, 2015	Feb. 28, 2015	Nov. 12, 2014	Oct. 31, 2014
Debt Instrument, Convertible, Conversion Price																					$ 0.0709
Debt Conversion, Converted Instrument, Amount																					$ 139,680																								$ 152,285	$ 0
Debt Instrument, Periodic Payment																					$ 154,798
Warrants Expire Period																																									5 years
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants																																									$ 3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																																									$ 0.0698
Debt Conversion, Converted Instrument, Shares Issued																					2,183,333
Stock Issued During Period, Shares, Issued for Services																		3,000,000
Stock Issued During Period, Value, Issued for Services																																													$ 741,276	$ 244,500
Common stock, authorized shares																																													2,000,000,000	2,000,000,000		10,000,000,000		100,000,000
Common stock, par value																																													$ 0.001	$ 0.001		$ 0.001		$ 0.001
Debt Conversion, Original Debt, Amount																																						$ 50,000
Class of Warrant or Right, Outstanding																																													3,000,000
Share Price																																													$ 0.0899
Common Stock [Member]
Debt Instrument, Convertible, Conversion Price																														$ 0.0025															$ 0.0025
Debt Conversion, Converted Instrument, Amount																														$ 25,000															$ 25,000
Debt Conversion, Converted Instrument, Shares Issued																														10,000,000															10,000,000
Stock Issued During Period, Shares, Issued for Services																																													19,258,316	1,915,000
Shares Issued, Price Per Share														$ 0.0025
Stock Issued During Period, Value, Issued for Services																																													$ 19,258	$ 1,915
Common stock, authorized shares																																																2,000,000,000		10,000,000,000
Common stock, par value																																																$ 0.001		$ 0.001
Stock Issued During Period, Shares, Conversion of Convertible Securities																																													181,185,110
Common Stock [Member] | Investment Banking Service Agreement [Member]
Stock Issued During Period, Shares, Issued for Services																																								500,000
Shares Issued, Price Per Share																																								$ 0.10
Stock Issued During Period, Value, Issued for Services																																								$ 50,000
Preferred Stock [Member]
Preferred stock, authorized shares																																													10,000,000
Preferred stock, par value																																													$ 0.01
Director [Member]
Debt Conversion, Converted Instrument, Amount														$ 14,000
Debt Conversion, Converted Instrument, Shares Issued														17,654,470
Investor [Member]
Stock Issued During Period, Shares, Issued for Services																						1,000,000											9,400,000	1,000,000	3,000,000
Shares Issued, Price Per Share																																	$ 0.0025	$ 0.0025	$ 0.001
Stock Issued During Period, Value, Issued for Services																																	$ 23,500	$ 2,500	$ 3,000
First Tranche [Member]
Stock Issued During Period, Shares, New Issues																																					7,426,000
Second Tranche [Member]
Stock Issued During Period, Shares, New Issues																			8,161,000
Debt Settlement Agreements [Member] | Director [Member]
Debt Conversion, Converted Instrument, Amount														$ 44,136
Debt Conversion, Converted Instrument, Shares Issued														17,654,470
Consultant [Member]
Stock Issued During Period, Shares, Issued for Services																		4,000,000		500,000				500,000		6,000,000										10,000,000									100,000
Shares Issued, Price Per Share																						$ 0.10														$ 0.008
Stock Issued During Period, Value, Issued for Services																						$ 100,000														$ 80,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																																											3,000,000						3,000,000		4,000,000
Consultant [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	500,000	6,758,316	500,000	1,000,000	6,758,316																		1,000,000																			300,000
Shares Issued, Price Per Share			$ 0.0706		$ 0.043																		$ 0.0445																			$ 0.20
Stock Issued During Period, Value, Issued for Services	$ 5,015	$ 88,446	$ 35,300	$ 7,265	$ 290,608																		$ 44,500																					$ 12,000			$ 48,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					3,379,158																		1,000,000
Share Price					$ 0.043																		$ 0.0445
Consultant [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price					$ 0.03																		$ 0.07
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					397.00%																		397.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term					60 years																		60 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					1.54%																		1.54%
Warrants and Rights Outstanding					$ 145,303																		$ 44,500
Prepaid Expense					101,080																		37,235
Share-based Compensation, Total					$ 44,223																		$ 7,265
Consultant One [Member]
Stock Issued During Period, Shares, Issued for Services																																													80,000
Consultant One [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																										250,000
Shares Issued, Price Per Share																																										$ 0.20
Stock Issued During Period, Value, Issued for Services																																										$ 50,000
Consultant Two [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																										137,500
Shares Issued, Price Per Share																																										$ 0.20
Stock Issued During Period, Value, Issued for Services																																										$ 27,500
Consultant Three [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																										10,000
Shares Issued, Price Per Share																																										$ 0.20
Stock Issued During Period, Value, Issued for Services																																										$ 2,000
Consultant Four [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																										150,000
Shares Issued, Price Per Share																																										$ 0.20
Stock Issued During Period, Value, Issued for Services																																										$ 30,000
Consultant Six [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																									300,000
Shares Issued, Price Per Share																																									$ 0.20
Stock Issued During Period, Value, Issued for Services																																									$ 60,000
Consultant Seven [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																									25,000
Shares Issued, Price Per Share																																									$ 0.20
Stock Issued During Period, Value, Issued for Services																																									$ 5,000
Consultant Eight [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																								200,000
Shares Issued, Price Per Share																																								$ 0.10
Stock Issued During Period, Value, Issued for Services																																								$ 13,333
Increase (Decrease) in Prepaid Expense																																								$ 6,667
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																																								3 years
Consultant Nine [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																								100,000
Shares Issued, Price Per Share																																								$ 0.10
Stock Issued During Period, Value, Issued for Services																																								$ 10,000
Consultant Ten [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																							30,000
Shares Issued, Price Per Share																																							$ 0.10
Stock Issued During Period, Value, Issued for Services																																							$ 3,000
Consultant Eleven [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services																																							25,000
Shares Issued, Price Per Share																																							$ 0.10
Stock Issued During Period, Value, Issued for Services																																							$ 2,500
Issue One [Member]
Debt Instrument, Convertible, Conversion Price						$ 0.0020	$ 0.0017	$ 0.0017	$ 0.0015	$ 0.0015	$ 0.0006	$ 0.0006	$ 0.0035		$ 0.0006	$ 0.0011	$ 0.0011								$ 0.0020	$ 0.0020	$ 0.0020	$ 0.0020	$ 0.0020		$ 0.0007	$ 0.0007	$ 0.0012
Debt Instrument, Periodic Payment						$ 4,271	$ 1,061	$ 15,534	$ 1,001	$ 14,675	$ 3,410	$ 3,266	$ 21,100		$ 3,446										$ 28,202	$ 10,145	$ 23,762	$ 8,260	$ 20,053		$ 4,044	$ 3,762	$ 6,000
Debt Conversion, Converted Instrument, Shares Issued																6,698,331	4,870,391
Debt Conversion, Original Debt, Amount																$ 7,368	$ 5,357
Stock Issued During Period, Shares, Conversion of Convertible Securities						2,135,450	622,504	9,110,833	674,141	9,882,013	6,200,000	5,937,563	6,089,544		6,265,964										14,100,870	5,072,740	12,001,242	4,171,808	10,127,576		5,655,958	5,700,000	5,194,805
Issue Two [Member]
Debt Instrument, Convertible, Conversion Price							$ 0.0019		$ 0.0015	$ 0.0015	$ 0.0015	$ 0.0035
Debt Instrument, Periodic Payment							$ 20,048		$ 14,678	$ 10,121	$ 6,443	$ 15,323
Stock Issued During Period, Shares, Conversion of Convertible Securities							10,414,660		9,884,155	6,815,185	4,338,384	4,422,257
Issue Three [Member]
Debt Instrument, Convertible, Conversion Price									$ 0.0016		$ 0.0015
Debt Instrument, Periodic Payment									$ 10,125		$ 1,011
Stock Issued During Period, Shares, Conversion of Convertible Securities									6,347,918		680,485
Loans from Directors [Member]
Debt Conversion, Converted Instrument, Amount														$ 27,000
Debt Conversion, Converted Instrument, Shares Issued														33,259,350
Loans from Directors [Member] | Director [Member]
Debt Instrument, Convertible, Conversion Price														$ 0.0025
Debt Conversion, Converted Instrument, Amount														$ 41,000
Loans from Directors [Member] | Debt Settlement Agreements [Member]
Debt Conversion, Converted Instrument, Amount														$ 83,148
Debt Conversion, Converted Instrument, Shares Issued														33,259,350
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues																																											8,161,000
Preferred stock, authorized shares																	500,000																												10,000,000	10,000,000
Preferred stock, par value																	$ 0.01																												$ 0.01	$ 0.01
Stock Issued During Period, Shares, Issued for Services																	500,000																												500,000	0
Shares Issued, Price Per Share																																											$ 0.00213
Stock Issued During Period, Value, Issued for Services																																											$ 1,067		$ 5,000	$ 0
Stock Issued During Period, Shares, Conversion of Convertible Securities																																													0
Series B Preferred Stock [Member]
Preferred stock, authorized shares																																													5	5
Preferred stock, par value																																													$ 0.01	$ 0.01
Stock Issued During Period, Shares, Issued for Services																																													1	0
Shares Issued, Price Per Share																																													$ 0.1165
Stock Issued During Period, Value, Issued for Services																																													$ 0	$ 0
Stock Issued During Period, Shares, Conversion of Convertible Securities																																													0

COMMITMENTS AND CONTINGIENCIES

COMMITMENTS AND CONTINGIENCIES (Details Textual) - USD ($)	Jul. 02, 2014	May. 31, 2015	Jan. 30, 2015	Jul. 31, 2014	Jul. 18, 2014	May. 31, 2014	Nov. 30, 2009	Jun. 30, 2015	Jun. 30, 2014	Apr. 30, 2015	Jul. 31, 2013
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense								$ 3,719	$ 11,016
Accrued Rent											$ 1,000
Sale of Stock, Number of Shares Issued in Transaction								15,587,000
Sale Of Stock Decreased liability Owed To Purchaser								$ 52,907
Debt Instrument, Convertible, Conversion Price	$ 0.0709
Payments for Fees					$ 50,000
Debt Conversion, Original Debt, Amount					$ 50,000
Interest Expense, Debt								405,000
Long-term Purchase Commitment, Period					24 months
Other Liabilities			$ 575,000
Debt Conversion, Converted Instrument, Shares Issued	2,183,333
Debt Conversion, Converted Instrument, Amount	$ 139,680							152,285	0
Conversion of Stock, Amount Converted								$ 71,370	$ 0
Common Stock [Member]
Commitments And Contingencies [Line Items]
Debt Instrument, Convertible, Conversion Price			$ 0.0025					$ 0.0025
Debt Conversion, Converted Instrument, Shares Issued			10,000,000					10,000,000
Debt Conversion, Converted Instrument, Amount			$ 25,000					$ 25,000
Promissory Note [Member]
Commitments And Contingencies [Line Items]
Debt Instrument, Convertible, Conversion Price								$ 0.0025
Debt Conversion, Original Debt, Amount						$ 25,000
Debt Conversion, Converted Instrument, Amount			50,000
Interest Payable			1,466
Conversion of Stock, Amount Converted			25,000					$ 25,000
Gains (Losses) on Extinguishment of Debt			51,466
Settlement Agreement [Member] | Promissory Note [Member]
Commitments And Contingencies [Line Items]
Interest Payable						1,466
Equity Purchase Agreement [Member] | Investor [Member]
Commitments And Contingencies [Line Items]
Percentage Of Common Stock Outstanding					9.99%
Percentage Of Market Price Of Common Stock					90.00%
Long-term Purchase Commitment, Amount					$ 5,000,000
Purchaser [Member]
Commitments And Contingencies [Line Items]
Debt Instrument, Unamortized Premium			310,000
Debt Instrument, Fee Amount			$ 67,000
Purchaser [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues								15,587,000
Purchaser [Member] | Settlement Agreement [Member]
Commitments And Contingencies [Line Items]
Payments for Fees						$ 25,000
Percentage Of Net Proceeds From Issuance Of Common Stock				65.00%
Percentage Of Common Stock Outstanding				9.99%
Loss Contingency, Damages Sought, Value				$ 627,998
Obligated to Issue Common Stock to Purchaser				$ 50,000
Percentage of Average Closing Bid Prices				75.00%
Purchaser [Member] | Equity Purchase Agreement [Member]
Commitments And Contingencies [Line Items]
Obligated to Issue Common Stock to Purchaser								$ 1,033,000
Lease Agreements [Member]
Commitments And Contingencies [Line Items]
Payments for Fees		$ 2,200
Royalty Agreement Terms [Member]
Commitments And Contingencies [Line Items]
Operating Leases Income Statement Revenue Percentage							2.00%
License Agreement Terms [Member]
Commitments And Contingencies [Line Items]
Accrued Rent										$ 21,000
Operating Leases Income Statement Revenue Percentage							5.00%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Feb. 04, 2015	Jul. 02, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Due to Related Parties, Current			$ 35,108	$ 60,350
Loans From Related Party			79,416	161,975
Debt Conversion, Converted Instrument, Shares Issued		2,183,333
Debt Conversion, Converted Instrument, Amount		$ 139,680	152,285	0
Debt Instrument, Convertible, Conversion Price		$ 0.0709
Conversion of Stock, Amount Converted			71,370	0
Loans from Directors [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	33,259,350
Debt Conversion, Converted Instrument, Amount	$ 27,000
Director [Member]
Related Party Transaction [Line Items]
Loans From Related Party			79,416	161,975
Debt Conversion, Converted Instrument, Shares Issued	17,654,470
Debt Conversion, Converted Instrument, Amount	$ 14,000
Director [Member] | Loans from Directors [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 41,000
Debt Instrument, Convertible, Conversion Price	$ 0.0025
Conversion of Stock, Amount Converted	$ 127,284
Gains (Losses) on Extinguishment of Debt	$ 86,455
Two Directors [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Current			$ 35,108	$ 60,350

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Textual)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Reimbursement On Goods And Service Tax Receivable Percentage	100.00%	100.00%

DERIVATIVE FINANCIAL INSTRUME46

DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS (Details)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014
Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility		408.00%
Risk-free interest rate		0.64%
Convertible Debt [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility			377.00%
Expected remaining term		1 year 8 months 12 days	2 years
Risk-free interest rate			0.70%
Convertible Debt [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility			216.00%
Expected remaining term		9 months 25 days	9 months 29 days
Risk-free interest rate			0.50%
Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	53.00%	408.00%	134.00%
Expected remaining term	5 years	3 years 3 months	4 years 3 months
Risk-free interest rate	0.40%	1.63%	0.47%

DERIVATIVE FINANCIAL INSTRUME47

DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Derivative [Line Items]
Embedded conversion option liability	$ 780,281
Fair value of liability for warrant derivative instruments	269,648	$ 158,244
Total	1,049,929	158,244	$ 0
Fair Value, Inputs, Level 1 [Member]
Derivative [Line Items]
Embedded conversion option liability	0
Fair value of liability for warrant derivative instruments	0	0
Total	0
Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Embedded conversion option liability	0
Fair value of liability for warrant derivative instruments	0	0
Total	0
Fair Value, Inputs, Level 3 [Member]
Derivative [Line Items]
Embedded conversion option liability	780,281
Fair value of liability for warrant derivative instruments	269,648	$ 158,244
Total	$ 1,049,929

DERIVATIVE FINANCIAL INSTRUME48

DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Balance at Beginning	$ 158,244	$ 0
Effects of foreign currency exchange rate changes	(42,796)	(2,519)
Initial fair value of embedded conversion option derivative liability recorded as debt discount	392,500	144,241
Initial fair value of embedded conversion option derivative liability recorded as change in fair value of ECO	1,082,567
Change in fair value included in statements of operations	(540,586)	16,522
Balance at Ending	$ 1,049,929	$ 158,244

DERIVATIVE FINANCIAL INSTRUME49

DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS (Details Textual)	Jun. 30, 2015USD ($)$ / sharesshares
Derivative Instruments And Hedging Activities [Line Items]
Class of Warrant or Right, Outstanding | shares	3,000,000
Share Price | $ / shares	$ 0.0899
Repricing option [Member]
Derivative Instruments And Hedging Activities [Line Items]
Convertible Debt	$ 335,000
Variable conversion pricing [Member]
Derivative Instruments And Hedging Activities [Line Items]
Convertible Debt	$ 87,500

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	Sep. 08, 2015	Sep. 04, 2015	Aug. 14, 2015	Jul. 15, 2015	Jul. 14, 2015	Dec. 04, 2014	Jul. 02, 2014	Sep. 24, 2015	Sep. 22, 2015	Sep. 18, 2015	Sep. 16, 2015	Sep. 01, 2015	Aug. 26, 2015	May. 19, 2015	Jan. 27, 2015	Jul. 18, 2014	Jun. 30, 2015	Jun. 30, 2014
Subsequent Event [Line Items]
Proceeds from Notes Payable															$ 50,000
Debt Conversion, Converted Instrument, Shares Issued							2,183,333
Debt Conversion, Original Debt, Amount																$ 50,000
Debt Instrument, Convertible, Conversion Price							$ 0.0709
Legal Fees															$ 2,500
Stock Issued During Period, Shares, Issued for Services						3,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger														55.00%
Promissory Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Unamortized Discount																	$ 415,467	$ 121,059
Subsequent Event [Member]
Subsequent Event [Line Items]
Repayments of Debt				$ 137,915
Debt Instrument, Annual Principal Payment				104,000
Debt Instrument, Periodic Payment, Interest				2,872
Debt Instrument Prepayment Penalty				$ 31,043
Subsequent Event [Member] | Secured Investor Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Unamortized Discount																	20,000
Secured Debt																	220,000
Proceeds from Issuance of Secured Debt																	201,997
Interest Proceeds Received																	$ 1,997
Shares Issued, Price Per Share																	$ 0.07
Subsequent Event [Member] | Three Notes Issued [Member]
Subsequent Event [Line Items]
Proceeds from Notes Payable					$ 352,500
Legal Fees					17,690
Net Proceeds From Notes Payable					$ 334,810
Subsequent Event [Member] | Conversion Notice [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			866,796						911,294	877,969	826,726	1,396,108	1,414,843
Debt Conversion, Original Debt, Amount			$ 20,500						$ 15,638	$ 15,694	$ 15,687	$ 25,723	$ 26,068
Debt Instrument, Convertible, Conversion Price			$ 0.02365						$ 0.01716	$ 0.017875	$ 0.018975	$ 0.018425	$ 0.018425
Subsequent Event [Member] | Conversion Notice One [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		849,263	879,585
Debt Conversion, Original Debt, Amount		$ 15,648	$ 20,802
Debt Instrument, Convertible, Conversion Price		$ 0.018425	$ 0.02365
Subsequent Event [Member] | Promissory Note [Member]
Subsequent Event [Line Items]
Debt Conversion, Original Debt, Amount								$ 1,200,000
Debt Instrument, Convertible, Conversion Price								$ 0.0346
Debt Instrument, Issuance Date								Sep. 24, 2015
Debt Instrument, Face Amount								$ 1,200,000
Debt Instrument, Increase, Accrued Interest								$ 180,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger								20.00%
Debt Instrument, Maturity Date, Description								The debenture has a maturity date of the earlier of: (i) the date on which the Company closes a subsequent equity offering in an amount greater than the principal amount of the Note; or (ii) June 24, 2016.
Subsequent Event [Member] | Consultant [Member]
Subsequent Event [Line Items]
Shares Issued, Price Per Share													$ 0.04
Stock Issued During Period, Shares, Issued for Services													560,000
Subsequent Event [Member] | Scientific Advisory Board [Member]
Subsequent Event [Line Items]
Shares Issued, Price Per Share	$ 0.0369
Stock Issued During Period, Shares, Issued for Services	600,000